Archives
Veratridine: A Benchmark Steroidal Alkaloid Neurotoxin fo...
Veratridine: A Benchmark Steroidal Alkaloid Neurotoxin for Sodium Channel Dynamics Research
Executive Summary: Veratridine is a steroidal alkaloid neurotoxin that binds site 2 of voltage-gated sodium channels, preventing inactivation and causing persistent depolarization (APExBIO). This property enables its use as a pharmacological tool in sodium channel dynamics, excitotoxicity, and seizure mechanism research (see prior review). Recent studies show Veratridine enhances UBXN2A protein levels and promotes mortalin-2 dependent cancer cell death in vitro and in vivo (APExBIO). Animal models demonstrate that 0.125 mg/kg intraperitoneal injection for 28 days upregulates UBXN2A and induces colon cancer cell death (Saito et al., 2025). Veratridine is best used for research, not for diagnostic or therapeutic applications.
Biological Rationale
Veratridine is extracted from Veratrum species and classified as a steroidal alkaloid neurotoxin (APExBIO). It targets voltage-gated sodium channels (VGSCs), essential for action potential initiation and propagation in excitable cells, including neurons, cardiomyocytes, and certain cancer cells. Persistent sodium current induced by veratridine models excitotoxicity and seizure mechanisms in preclinical systems. In oncology, veratridine-mediated sodium influx modulates protein signaling (e.g., UBXN2A, mortalin-2), influencing cancer cell viability (APExBIO). Chamber-specific differences in sodium channel expression between left and right ventricular cardiomyocytes further justify its use in cardiac research (Saito et al., 2025).
Mechanism of Action of Veratridine
Veratridine binds to site 2 on the alpha subunit of voltage-gated sodium channels, stabilizing the open state and preventing channel inactivation (APExBIO). This leads to persistent Na+ influx, continuous membrane depolarization, and increased excitability in neurons and myocytes. In disease models, this mechanism is exploited to study sodium-dependent pathologies, including epileptiform activity, cardiac arrhythmias, and cancer cell apoptosis (see contrasting translational overview). The effect is dose-dependent, with higher concentrations producing increased depolarization and cytotoxicity. Veratridine does not directly affect other ion channels at research concentrations.
Evidence & Benchmarks
- Veratridine causes persistent activation of voltage-gated sodium channels by binding to site 2, resulting in prolonged depolarization of excitable membranes (APExBIO).
- In vitro, veratridine increases UBXN2A protein levels in a dose-dependent manner and triggers mortalin-2 dependent cancer cell death (APExBIO).
- Animal studies confirm that intraperitoneal administration of veratridine (0.125 mg/kg, 28 days) upregulates UBXN2A and induces colon cancer cell death (Saito et al., 2025).
- Veratridine is highly soluble in DMSO (>33.69 mg/ml, >10 mM) and appears as a white solid with a molecular weight of 673.79 g/mol (APExBIO).
- In cardiac modeling, veratridine supports sodium channel functional assays to distinguish left versus right ventricular cardiomyocyte phenotypes (Saito et al., 2025).
- Veratridine is a reference compound in screening assays for sodium channel blockers, including those for antiepileptic and antiarrhythmic drug development (see technical applications).
Applications, Limits & Misconceptions
Veratridine is widely used in sodium channel dynamics research, excitotoxicity studies, seizure mechanism modeling, and cancer research.
- Neuroscience and Excitability: Veratridine induces persistent sodium currents for modeling neuronal hyperexcitability and screening channel blockers.
- Cardiac Research: Used to probe chamber-specific sodium channel function in left and right ventricular cardiomyocytes, supporting disease modeling (Saito et al., 2025).
- Cancer Chemosensitivity: Enhances UBXN2A and triggers mortalin-2 dependent apoptosis, especially in colon cancer cell lines (APExBIO).
- Screening Assays: Benchmark compound for sodium channel blocker efficacy assays (see application details).
Common Pitfalls or Misconceptions
- Veratridine is not suitable for diagnostic or therapeutic use in humans due to its potent neurotoxicity (APExBIO).
- Long-term storage of veratridine solutions is not recommended; use prepared solutions promptly for reproducibility (APExBIO).
- Veratridine does not directly modulate potassium or calcium channels at standard research concentrations.
- Species-specific differences in sodium channel isoform expression can affect experimental outcomes; confirm channel subtype in your system (Saito et al., 2025).
- Veratridine-induced cytotoxicity may mask subtle drug effects in multi-compound screens; titrate carefully.
This article extends previous reviews (see prior benchmark overview) by integrating new evidence on cancer chemosensitivity and cardiomyocyte chamber specificity, and clarifies technical boundaries highlighted in recent translational perspectives.
Workflow Integration & Parameters
Veratridine (SKU: B7219, APExBIO) is supplied as a white solid. It is soluble in DMSO at concentrations exceeding 33.69 mg/ml (>10 mM). For cell studies, prepare fresh solutions and use immediately to avoid degradation. Store dry powder at -20°C for optimal stability. For in vivo studies, typical dosing ranges from 0.05–0.2 mg/kg intraperitoneally, with 0.125 mg/kg for 28 days used in cancer models (Saito et al., 2025). For sodium channel assays, titrate concentration to achieve persistent depolarization without excessive toxicity; 1–10 μM is common for cell-based assays. Always include vehicle controls (DMSO) and confirm channel subtype expression. For screening sodium channel blockers, veratridine serves as a positive control to benchmark assay sensitivity (see assay comparisons).
Conclusion & Outlook
Veratridine remains a gold-standard tool for sodium channel dynamics research and chemosensitivity modulation. Its actions on persistent sodium currents underpin applications in neuroscience, cardiac modeling, and oncology. Integration with chamber-specific cardiomyocyte protocols and new protein markers (e.g., UBXN2A) expands its utility. However, careful handling, titration, and species-specific considerations are required for robust results. For product data, application notes, and ordering, refer to the Veratridine B7219 kit from APExBIO. For extended perspectives on translational and mechanistic strategy, see Veratridine at the Translational Edge, which provides experimental design considerations beyond the core facts presented here.